Item 8.01 Other Events.
On November 26, 2021, Ocugen, Inc. (the "Company") issued a press release
providing an Update on its Investigational New Drug Application with U.S. FDA to
initiate a phase 3 clinical trial evaluating COVID-19 vaccine candidate COVAXIN™
(BBV152). A copy of this press release is filed herewith as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are being filed herewith:
(d) Exhibits
Exhibit No. Document
99.1 Press Release of Ocugen, Inc. dated November 26, 2021.
Cover Page Interactive Data File (embedded within the Inline XBRL
104 document).
1
© Edgar Online, source Glimpses